Selumetinib is a non-ATP competitive inhibitor of MEK-1 (IC50 = 14 nM). This compound inactivates the phosphorylation of ERK1/2 (IC50 < 40 nM). Selumetinib has little effect on p38, c-Jun-NH2-kinase, or the MEK/ERK5 pathways.
Crystalline granules or crystalline powder
Soluble in DMSO (92 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), and ethanol (<1 mg/ml at 25 °C).
bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of
DreadenDreaden, EC. et al. (PubMed 26034127) co-encapsulated AZD6244 (Selumetinib), an inhibitor of Mek1/2, and PX-866 (sc-396764), an inhibitor of PI3K, to create tumor-targeting nanoscale drug formulation-layer-by-layer (LbL) nanoparticles. Combined MAPK and PI3K axis blockade from the nanoscale formulations was synergistically toxic toward triple-negative breast (MDA-MB-231) and RAS-mutant lung tumor cells (KP7B) in vitro. -SCBT Publication Review
To place an order using RMB or to ship to mainland China, please visit www.scbio.cn
Create a new account
Email address already exists, please enter a new valid email address.Hide
USE YOUR SOCIAL NETWORK
Create an account quickly and easily with your preferred social network account. You won't have to remember an extra name and password.
Creating an account with us makes your shopping experience much easier and faster. You can save favorites, save cart, check order status and speed through checkout with saved addresses, payment methods and more.